Merck's Combination Urinary Cancer Therapy Receives EMA's Committee Nod

MT Newswires Live07-26

Merck (MRK) said on Friday that the European Medicines Agency's Committee recommended approval of Keytruda, combined with Pfizer (PFE) and Astellas Pharma's Padcev, for first-line treatment of adults with unresectable or metastatic urothelial carcinoma.

The recommendation is based on data from the first interim analysis of the Phase 3 study conducted in collaboration with Pfizer and Astellas.

The study showed that Keytruda plus Padcev demonstrated statistically significant and clinically meaningful improvements in overall survival and progression-free survival in patients compared to platinum-based chemotherapy.

Price: 125.88, Change: +0.03, Percent Change: +0.02

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment